Preventive treatments for breast cancer: recent developments

• Autores: José Enrique Alés Martínez, Amparo Ruiz, José Ignacio Chacón López Muñiz, Ana Lluch Hernández, Manuel Ramos Vázquez, Octavi Córdoba Cardona, E. Aguirre Ortega, Agustí Barnadas i Molins, Carlos Jara Sánchez, Santiago González Santiago, A. Plazaola Alcibar, Jesús Florián Jericó, Raquel Andrés Conejero, Pedro Sánchez Rovira, Adolfo Frau Llopis
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 17, Nº. 4 (April), 2015, págs. 257-263
• Idioma: inglés
• Enlaces
  • Texto completo
• Resumen

  • Breast cancer is a burden for western societies, and an increasing one in emerging economies, because of its high incidence and enormous psychological, social, sanitary and economic costs. However, breast cancer is a preventable disease in a significant proportion. Recent developments in the armamentarium of effective drugs for breast cancer prevention (namely exemestane and anastrozole), the new recommendation from the National Institute for Health and Care Excellence to use preventative drugs in women at high risk as well as updated Guidelines from the US Preventive Services Task Force and the American Society of Clinical Oncology should give renewed momentum to the pharmacological prevention of breast cancer. In this article we review recent major developments in the field and examine their ongoing repercussion for breast cancer prevention. As a practical example, the potential impact of preventive measures in Spain is evaluated and a course of practical actions is delineated.